Multiple Myeloma: Linvoseltamab Treatment Study

We are investigating the safety and effectiveness of linvoseltamab in patients with newly diagnosed multiple myeloma who have not yet received treatment. This study will help us understand how well this new therapy works for different patient groups.

Efficacy phase (II)No PlaceboPartially RemoteStandard MedicinesOralInjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dexamethasone
Dexamethasone is a steroid that reduces inflammation and suppresses the immune system to treat allergic, inflammatory, and autoimmune conditions.
Linvoseltamab
Linvoseltamab is an antibody-based substance that helps the immune system target and kill multiple myeloma cancer cells.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hopital Prive D Antony
Département d’Hématologie
Antony, France
Centre Hospitalier Universitaire De Lille
Service des Maladies du Sang
La Madeleine, France
Centre Hospitalier Universitaire De Montpellier
Département Hématologie Clinique
Montpellier, France
Sponsor: Regeneron Pharmaceuticals Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.